Impact of Concomitant Hormone Therapy on the Diagnostic Performance of ¹⁸F-Piflufolastat PET/CT in Prostate Cancer Patients: A Sub-Group Analysis of OSPREY Cohort B.

ABSTRACT:

Background

This study investigates the impact of hormone therapy (HT) on the diagnostic performance of ¹⁸F-piflufolastat PET/CT in OSPREY (NCT02981368) cohort B patients with recurrent or metastatic prostate cancer.

Methods

¹⁸F-piflufolastat PET/CT was evaluated in OSPREY cohort B patients (n = 117 men) with elevated prostate-specific antigen (PSA) levels and suspected local recurrence or metastatic disease on baseline conventional imaging. Patients were stratified based on HT status, and sensitivity and positive predictive value (PPV) were determined for the subset of 93 patients with evaluable pathology. Baseline serum PSA and testosterone levels were determined within 30 days before dosing using standardized laboratory methods.

Results

In OSPR

SUBMITTER: Saperstein L 

PROVIDER: S-EPMC12211537 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature